Why the study?
Application of blood biomarkers for hypertension in sub-Saharan Africa has been limited by a lack of blood collection facilities, making dried blood spots a potentially feasible alternative.
Are dried blood spot biomarkers of oxidative stress and inflammation associated with blood pressure changes in rural Senegalese women with incident hypertension?
Are dried blood spot biomarkers of oxidative stress and inflammation associated with blood pressure changes in rural Senegalese women with incident hypertension?
Dried blood spot measurements of CRP and MDA are feasible and significantly associated with current and future systolic blood pressure, offering a practical tool for hypertension management in resource-limited settings.
Answers are grounded in this paper and cite their sources.
DBS may enable CRP and oxidative stress assessment in rural sub-Saharan settings without phlebotomy; leaves open their predictive role in incident hypertension.
Blood biomarkers of oxidative stress and inflammation have been associated with increased risk of hypertension development; yet their application in sub-Saharan Africa has been limited due to the lack of blood collection facilities. In this study, we evaluated the usefulness of dried blood spots (DBS), a more feasible alternative to venous blood, in rural sub-Saharan residents. We recruited 342 women with incident hypertension from rural Senegal, and measured C-reactive protein (CRP) and malondialdehyde (MDA) in DBS and concurrent blood pressure (BP) at baseline and 1-year follow-up. Associations of DBS biomarkers with current levels of and 1-year changes in BP were examined after adjusting for demographic, medical, and socioeconomic covariates. DBS concentrations of MDA were significantly associated with concurrent systolic BP (SBP) (p < 0.05), while DBS baseline concentrations of CRP were associated with longitudinal changes in SBP between baseline and follow-up. Compared to participants with baseline CRP < 1 mg/L, those with CRP of 1–3 mg/L and 3–10 mg/L had 2.11 mmHg (95%CI: −2.79 to 7.02 mmHg) and 4.68 mmHg (95%CI: 0.01 to 9.36 mmHg) increases in SBP at follow-up, respectively. The results support the use of DBS biomarkers for hypertension prevention and control, especially in settings with limited clinical resources.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: